Overview

NICE no longer plans to develop guidance on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.

Next review: If NICE is notified about this topic again then it will follow the NICE topic prioritisation process.

Evoke spinal cord stimulator overview The evoke spinal cord stimulator (SCS) is a rechargeable, implantable, closed loop stimulator for chronic pain management. The system is made up of an implantable closed loop stimulator (an external stimulator is used during an initial trial period), 1 or 2 leads connecting the stimulator to the spinal cord, a remote control for manually changing stimulation and a charging kit. The evoke stimulator (external or implantable) is programmed to deliver therapeutic SCS utilising feedback control by the Evoke Clinical interface and Evoke Clinical system Transceiver. The Evoke system utilises feedback control by recording activation of neural tissue and automatically adjusting stimulation to ensure it remains within the therapeutic range. The Evoke system is intended to replace conventional SCS for adults with chronic, intractable pain. The company claims the device offers patients improved pain relief and quality of life. The company also claim the technology has the potential to reduce costs related to opioid medication and the number of hospital visits.

Status:
Discontinued
Technology type:
Device
Decision:
Selected
Prioritisation programme:
HealthTech
Rationale:

  

ID number:
567

Project Team

Project lead
Rebecca Brookfield

Email enquiries

If you have any queries please email MedTech@nice.org.uk

Timeline

Key events during the development of the guidance:

Date Update
25 June 2026 Discontinued
25 June 2026 Overview - Note added to the project documents
16 March 2023 Suspended
18 June 2021 Awaiting development. Status change linked to topic prioritisation decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual